Antidonor Antibody in Patients Receiving ABO-Identical and HLA-Mismatched Living Donor Liver Transplants: Effect on Survival
ABSTRACT We retrospectively determined the correlation of results of lymphocyte crossmatch tests by direct complement-dependent cytotoxicity, to the outcomes of 585 consecutive ABO-identical and human leukocyte antigen (HLA)-mismatched living donor liver transplants (LDLTs) (male:female=276:309; median age, 18 years). Crossmatch test results were positive in 14 recipients (2.4%). Patient survival at eight years in the crossmatch-positive group was significantly lower than in the crossmatch-negative group (positive group, 56.3%; negative group, 77.6%; P=0.014). The survival at five years of the crossmatch-positive group was significantly lower than the negative group in both older recipients (>or=18 years of age: positive group, 41.7%; negative group, 76.4%; P=0.0065), and female recipients (positive group, 37.5%; negative group, 81.9%; P=3.3x10). We conclude that antidonor antibodies have adverse effects on the clinical outcome of LDLTs, and that being female and/or older aged (>or=18 years of age) are risk factors for LDLT.
- SourceAvailable from: YoungRok Choi
[Show abstract] [Hide abstract]
- "However, Donaldson et al. (4) later reported an apparently strong association between vanishing duct syndrome and preformed HLA class I antibody. Thus, negative survival outcomes of grafts with positive lymphocyte XM is still a matter of debate in the field of LT (2, 5, 6, 7, 8). "
ABSTRACT: Several studies have suggested that a positive lymphocyte cross-matching (XM) is associated with low graft survival rates and a high prevalence of acute rejection after adult living donor liver transplantations (ALDLTs) using a small-for-size graft. However, there is still no consensus on preoperative desensitization. We adopted the desensitization protocol from ABO-incompatible LDLT. We performed desensitization for the selected patients according to the degree of T lymphocyte cross-match titer, model for end-stage liver disease (MELD) score, and graft liver volume. We retrospectively evaluated 230 consecutive ALDLT recipients for 5 yr. Eleven recipients (4.8%) showed a positive XM. Among them, five patients with the high titer (> 1:16) by antihuman globulin-augmented method (T-AHG) and one with a low titer but a high MELD score of 36 were selected for desensitization: rituximab injection and plasmapheresis before the transplantation. There were no major side effects of desensitization. Four of the patients showed successful depletion of the T-AHG titer. There was no mortality and hyperacute rejection in lymphocyte XM-positive patients, showing no significant difference in survival outcome between two groups (P=1.000). In conclusion, this desensitization protocol for the selected recipients considering the degree of T lymphocyte cross-match titer, MELD score, and graft liver volume is feasible and safe. Graphical AbstractJournal of Korean Medical Science 05/2014; 29(5):640-7. DOI:10.3346/jkms.2014.29.5.640 · 1.27 Impact Factor
[Show abstract] [Hide abstract]
- "On the other hand, such effect is controversial in liver transplantation, even in living donor liver transplantation (LDLT)  . We previously reported the negative effect of preformed donor-specific antibody (DSA) in LDLT and demonstrated that the risk factors for mortality were an adult recipient and a female gender  . However, our previous studies did not include determination of the HLA targeted by the preformed DSA as well as analysis of the relationship between the amount of HLA-specific DSA and clinical outcome. "
ABSTRACT: Aim: To analyze the risks of preoperatively produced donor-specific antibody (DSA) in liver transplantation. Methods: DSA was assessed using direct complement-dependent cytotoxicity (CDC) and anti-human globulin- (AHG-) CDC tests, as well as the Luminex Single Antigen assay. Among 616 patients undergoing blood type identical or compatible living donor liver transplantation (LDLT), 21 patients were positive for CDC or AHG-CDC tests, and the preserved serum from 18 patients was examined to determine targeted Class I and II antigens. The relationships between the mean fluorescence intensity (MFI) of DSA and the clinical outcomes were analyzed. Results: Patients were divided into 3 groups according to the MFI of anti-Class I DSA: high (11 patients with MFI > 10,000), low (2 patients with MFI < 10,000), and negative (5 patients) MFI groups. Six of 11 patients with high Class-I DSA showed positive Class-II DSA. Hospital death occurred in 7 patients of the high MFI group. High MFI was a significant risk factor for mortality (P = 0.0155). Univariate analysis showed a significant correlation between MFI strength and C4d deposition (P = 0.0498). Conclusions: HLA Class I DSA with MFI > 10,000 had a significant negative effect on the clinical outcome of patients with preformed DSA in LDLT.Clinical and Developmental Immunology 05/2013; 2013:972705. DOI:10.1155/2013/972705 · 2.93 Impact Factor
[Show abstract] [Hide abstract]
- "Some authors have reported that a positive TLC before LDLT is closely related to a higher ACR [5,20,23] and lower graft or patient survival [5,23,24]. They recommend that a pretransplant positive crossmatch be regarded as a factor predicting lower liver allograft survival and be used as an indicator for the use of more aggressive and individualized immunosuppressive regimens [5,19,23,25,26]. However, some previous studies have demonstrated that a pretransplant positive TLC does not negatively affect graft or patient survival in LDLT and does not increase ACR in pediatric LDLT . "
ABSTRACT: There is controversy concerning the effect of a positive T-lymphocytotoxic crossmatch (TLC) on clinical outcomes in adult living donor liver transplantation (LDLT). The aim of this study was to investigate the effect of TLC on clinical outcomes in LDLT and to determine how long a pretransplant positive TLC continues after liver transplantation (LT). Between January 2005 and June 2010, 219 patients underwent adult LDLT at National Cancer Center. The TLC test was routinely performed before LDLT. TLC test results were positive in 8 patients (3.7%). Patients were divided into 2 groups according to the result of TLC: positive TLC (n = 8) and negative TLC (n = 211) groups. All patients with a pretransplant positive TLC (n = 6) underwent a TLC test every week until negative conversion of TLC, except 2 patients who refused to receive the TLC test. Acute cellular rejection, surgical complications and patient or graft survival were not significantly different between both groups. All patients with a positive TLC (n = 6) had a posttransplant negative TLC. The median time to negative conversion of TLC was 1.5 weeks (range, 1 to 3 weeks). A pretransplant positive TLC does not affect clinical outcomes in adult LDLT. Moreover, T-lymphocytotoxic cross-reactivity disappeared within 3 weeks (range, 1 to 3 weeks) after LT.Journal of the Korean Surgical Society 04/2013; 84(4):245-51. DOI:10.4174/jkss.2013.84.4.245 · 0.73 Impact Factor